Outcomes of this analysis indicated that patients receiving exemestane, the steroidal aromatase inhibitor, had a statistically significant decrease in the incidence of AD and dementia compared with patients receiving the nonsteroidal drugs anastrozole and letrozole (eFigure 4 in the Supplement). Here, CYP19A1 is linked to dementia.